Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Its lead candidate, KYV-101, is an autologous CD19 CAR T-cell therapy for stiff person syndrome, myasthenia gravis, and other autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell candidate using whole blood rapid manufacturing, and KYV-201, an allogeneic CD19 CAR T-cell candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy. Formerly known as BAIT Therapeutics, Inc., it changed its name to Kyverna Therapeutics, Inc. in October 2019. The company was incorporated in 2018 and is headquartered in Emeryville, California.

Biotech & Genomic Medicine▲

Jacob Funds adds Kyverna Therapeutics to portfolio, sees potential in stiff person syndrome CAR-T therapy

Jacob Funds disclosed a new position in Kyverna Therapeutics during the first quarter of 2026, highlighting the biotech's lead candidate for stiff person syndrome as a potential first-of-its-kind CAR-T cell therapy to reach FDA approval. The firm noted early patient data showed meaningful symptom improvement in the rare neurologic disease, which currently has no approved treatment. Jacob Funds also holds Cabaletta Bio and Cartesian Therapeutics, aiming for broad exposure to next-generation CAR-T programs that could expand into larger autoimmune indications such as myasthenia gravis and multiple sclerosis. Kyverna shares gained 177.59% over the past 52 weeks and closed at $9.91 on July 8, 2026, with a market capitalization of $602.48 million.

KYTX ▲

Biotech & Genomic Medicine

Insider Monkey·71dRead more →